An update on primary ovarian insufficiency

Science China Life Sciences

Volumn 55, Issue 8, 2012, Pages 677-686

  Jin, Min ^a   Yu, YiQi ^a   Huang, HeFeng ^a  

^a Zhejiang University School of Medicine   (China)

Author keywords

environmental factors; genetic aberrations; hormone replacement therapy; ovary preservation; primary ovarian insufficiency

Indexed keywords

AUTOIMMUNITY; DANGEROUS GOODS; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; FEMALE INFERTILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; INBORN ERROR OF METABOLISM; INFERTILITY THERAPY; PREGNANCY; PREMATURE OVARIAN FAILURE; REVIEW; RISK FACTOR; X CHROMOSOME;

AUTOIMMUNITY; CHROMOSOMES, HUMAN, X; ESTROGEN REPLACEMENT THERAPY; FEMALE; HAZARDOUS SUBSTANCES; HIV INFECTIONS; HUMANS; IATROGENIC DISEASE; INFERTILITY, FEMALE; MENOPAUSE, PREMATURE; METABOLISM, INBORN ERRORS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK FACTORS;

EID: 84865832628     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4355-2     Document Type: Review

References (119)

1. Nelson L M. Clinical practice. Primary ovarian insufficiency. N Engl J Med, 2009, 360: 606-614.
2. Cooper A R, Baker V L, Sterling E W, et al. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril, 2011, 95: 1890-1897.
3. van Noord P A, Dubas J S, Dorland M, et al. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril, 1997, 68: 95-102.
4. Coulam C B, Adamson S C, Annegers J F. Incidence of premature ovarian failure. Obstet Gynecol, 1986, 67: 604-606.
5. Skillern A, Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure. Sex Dev, 2008, 2: 228-243.
6. Bachelot A, Rouxel A, Massin N, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol, 2009, 161: 179-187.
7. Rebar R W, Erickson G F, Yen S S. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril, 1982, 37: 35-41.
8. Rebar R W, Connolly H V. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril, 1990, 53: 804-810.
9. Nelson L M, Anasti J N, Kimzey L M, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab, 1994, 79: 1470-1475.
10. Bakalov V K, Anasti J N, Calis K A, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril, 2005, 84: 958-965.
11. Santoro N. Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab, 2011, 96: 3281-3288.
12. Wellons M. Cardiovascular disease and primary ovarian insufficiency. Semin Reprod Med, 2011, 29: 328-341.
13. Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril, 2008, 90: S219-225.
14. Younis J S. Ovarian aging and implications for fertility female health. Minerva Endocrinol, 2012, 37: 41-57.
15. Goswami D, Conway G S. Premature ovarian failure. Hum Reprod Update, 2005, 11: 391-410.
16. Morita Y, Tilly J L. Oocyte apoptosis: like sand through an hourglass. Dev Biol, 1999, 213: 1-17.
17. Sullivan S D, Castrillon D H. Insights into primary ovarian insufficiency through genetically engineered mouse models. Semin Reprod Med, 2011, 29: 283-298.
18. Adhikari D, Zheng W, Shen Y, et al. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet, 2010, 19: 397-410.
19. Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature, 2004, 428: 145-150.
20. van Kasteren Y M, Hundscheid R D, Smits A P, et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod, 1999, 14: 2455-2459.
21. Davis C J, Davison R M, Payne N N, et al. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect: opinion. Hum Reprod, 2000, 15: 2418-2422.
22. Hunter J E, Epstein M P, Tinker SW, et al. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol, 2008, 32: 553-559.
23. Wittenberger M D, Hagerman R J, Sherman S L, et al. The FMR1 premutation and reproduction. Fertil Steril, 2007, 87: 456-465.
24. Murabito J M, Yang Q, Fox C, et al. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab, 2005, 90: 3427-3430.
25. Simpson J L. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci, 2008, 1135: 146-154.
26. Dixit H, Rao L, Padmalatha V, et al. Genes governing premature ovarian failure. Reprod Biomed Online, 2010, 20: 724-740.
27. Zinn A R. The X chromosome and the ovary. J Soc Gynecol Investig, 2001, 8: S34-36.
28. Hens L, Devroey P, van Waesberghe L, et al. Chromosome studies and fertility treatment in women with ovarian failure. Clin Genet, 1989, 36: 81-91.
29. Kawano Y, Narahara H, Matsui N, et al. Premature ovarian failure associated with a Robertsonian translocation. Acta Obstet Gynecol Scand, 1998, 77: 467-469.
30. Burton K A, van Ee C C, Purcell K, et al. Autosomal translocation associated with premature ovarian failure. J Med Genet, 2000, 37: E2.
31. Gleicher N, Weghofer A, Kim A, et al. The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve. PLoS ONE, 2012, 7: e33638.
32. Allen E G, Sullivan A K, Marcus M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod, 2007, 22: 2142-2152.
33. Murray A, Ennis S, Morton N. No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers. Am J Hum Genet, 2000, 67: 253-254; author reply 256-258.
34. Sullivan A K, Marcus M, Epstein M P, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod, 2005, 20: 402-412.
35. Sullivan S D, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med, 2011, 29: 299-307.
36. Allen E G, He W, Yadav-Shah M, et al. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet, 2004, 114: 439-447.
37. Bretherick K L, Fluker M R, Robinson W P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet, 2005, 117: 376-382.
38. Bretherick K L, Hanna C W, Currie L M, et al. Estrogen receptor alpha gene polymorphisms are associated with idiopathic premature ovarian failure. Fertil Steril, 2008, 89: 318-324.
39. Vujovic S. Aetiology of premature ovarian failure. Menopause Int, 2009, 15: 72-75.
40. Otsuka F, McTavish K J, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev, 2011, 78: 9-21.
41. McNatty K P, Juengel J L, Reader K L, et al. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function in ruminants. Reproduction, 2005, 129: 481-487.
42. Dube J L, Wang P, Elvin J, et al. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol, 1998, 12: 1809-1817.
43. Aaltonen J, Laitinen M P, Vuojolainen K, et al. Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9B are expressed in oocytes during early folliculogenesis. J Clin Endocrinol Metab, 1999, 84: 2744-2750.
44. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet, 2004, 75: 106-111.
45. Di Pasquale E, Rossetti R, Marozzi A, et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab, 2006, 91: 1976-1979.
46. Dixit H, Rao L K, Padmalatha V V, et al. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet, 2006, 119: 408-415.
47. Laissue P, Christin-Maitre S, Touraine P, et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol, 2006, 154: 739-744.
48. Zhao Z Z, Painter J N, Palmer J S, et al. Variation in bone morphogenetic protein 15 is not associated with spontaneous human dizygotic twinning. Hum Reprod, 2008, 23: 2372-2379.
49. Inagaki K, Shimasaki S. Impaired production of BMP-15 and GDF-9 mature proteins derived from proproteins WITH mutations in the proregion. Mol Cell Endocrinol, 2010, 328: 1-7.
50. Spicer L J, Aad P Y, Allen D T, et al. Growth differentiation factor 9 (GDF9) stimulates proliferation and inhibits steroidogenesis by bovine theca cells: influence of follicle size on responses to GDF9. Biol Reprod, 2008, 78: 243-253.
51. Orisaka M, Tajima K, Tsang B K, et al. Oocyte-granulosa-theca cell interactions during preantral follicular development. J Ovarian Res, 2009, 2: 9.
52. Dong J, Albertini D F, Nishimori K, et al. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature, 1996, 383: 531-535.
53. Huang Q, Cheung A P, Zhang Y, et al. Effects of growth differentiation factor 9 on cell cycle regulators and ERK42/44 in human granulosa cell proliferation. Am J Physiol Endocrinol Metab, 2009, 296: E1344-1353.
54. Galloway S M, McNatty K P, Cambridge L M, et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet, 2000, 25: 279-283.
55. Hanrahan J P, Gregan S M, Mulsant P, et al. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod, 2004, 70: 900-909.
56. Nicol L, Bishop S C, Pong-Wong R, et al. Homozygosity for a single base-pair mutation in the oocyte-specific GDF9 gene results in sterility in Thoka sheep. Reproduction, 2009, 138: 921-933.
57. Montgomery G W, Zhao Z Z, Marsh A J, et al. A deletion mutation in GDF9 in sisters with spontaneous DZ twins. Twin Res, 2004, 7: 548-555.
58. Palmer J S, Zhao Z Z, Hoekstra C, et al. Novel variants in growth differentiation factor 9 in mothers of dizygotic twins. J Clin Endocrinol Metab, 2006, 91: 4713-4716.
59. Pisarska M D, Kuo F T, Bentsi-Barnes I K, et al. LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity. Am J Physiol Endocrinol Metab, 2010, 299: E101-109.
60. Matthews C H, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet, 1993, 5: 83-86.
61. Aittomaki K, Lucena J L, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell, 1995, 82: 959-968.
62. Liu J Y, Gromoll J, Cedars M I, et al. Identification of allelic variants in the follicle-stimulating hormone receptor genes of females with or without hypergonadotropic amenorrhea. Fertil Steril, 1998, 70: 326-331.
63. Takahashi K, Ozaki T, Okada M, et al. Increased prevalence of luteinizing hormone beta-subunit variant in patients with premature ovarian failure. Fertil Steril, 1999, 71: 96-101.
64. Lofrano-Porto A, Barra G B, Giacomini L A, et al. Luteinizing hormone beta mutation and hypogonadism in men and women. N Engl J Med, 2007, 357: 897-904.
65. Latronico A C, Chai Y, Arnhold I J, et al. A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor. Mol Endocrinol, 1998, 12: 442-450.
66. Chand A L, Harrison C A, Shelling A N. Inhibin and premature ovarian failure. Hum Reprod Update, 2010, 16: 39-50.
67. Prakash G J, Ravi Kanth V V, Shelling A N, et al. Mutational analysis of inhibin alpha gene revealed three novel variations in Indian women with premature ovarian failure. Fertil Steril, 2010, 94: 90-98.
68. MacNaughton J, Banah M, McCloud P, et al. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol (Oxf), 1992, 36: 339-345.
69. Petraglia F, Hartmann B, Luisi S, et al. Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea. Fertil Steril, 1998, 70: 907-912.
70. Soules M R, Battaglia D E, Klein N A. Inhibin and reproductive aging in women. Maturitas, 1998, 30: 193-204.
71. Waggoner D D, Buist N R, Donnell G N. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis, 1990, 13: 802-818.
72. Schuh-Huerta S M, Johnson N A, Rosen M P, et al. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod, 2012, 27: 594-608.
73. Christin-Maitre S, Pasquier M, Donadille B, et al. Premature ovarian failure. Ann Endocrinol (Paris), 2006, 67: 557-566.
74. Cordts E B, Christofolini D M, Dos Santos A A, et al. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet, 2011, 283: 635-643.
75. Forges T, Monnier-Barbarino P, Leheup B, et al. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update, 2006, 12: 573-584.
76. Kaufman F R, Kogut M D, Donnell G N, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med, 1981, 304: 994-998.
77. Rubio-Gozalbo M E, Gubbels C S, Bakker J A, et al. Gonadal function in male and female patients with classic galactosemia. Hum Reprod Update, 2010, 16: 177-188.
78. Levy H L. Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. Turk J Pediatr, 1996, 38: 335-344.
79. Gubbels C S, Kuppens S M, Bakker J A, et al. Pregnancy in classic galactosemia despite undetectable anti-Mullerian hormone. Fertil Steril, 2009, 91: 1293-1296.
80. Sanders R D, Spencer J B, Epstein M P, et al. Biomarkers of ovarian function in girls and women with classic galactosemia. Fertil Steril, 2009, 92: 344-351.
81. Gubbels C S, Thomas C M, Wodzig W K, et al. FSH isoform pattern in classic galactosemia. J Inherit Metab Dis, 2011, 34: 387-390.
82. Hoek A, Schoemaker J, Drexhage H A. Premature ovarian failure and ovarian autoimmunity. Endocr Rev, 1997, 18: 107-134.
83. Smith J A, Vitale S, Reed G F, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol, 2004, 122: 151-156.
84. Husebye E S, Lovas K. Immunology of Addison's disease and premature ovarian failure. Endocrinol Metab Clin North Am, 2009, 38: 389-405.
85. Cheng M H, Nelson L M. Mechanisms and models of immune tolerance breakdown in the ovary. Semin Reprod Med, 2011, 29: 308-316.
86. La Marca A, Brozzetti A, Sighinolfi G, et al. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol, 2010, 22: 277-282.
87. Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med, 2002, 11: 585-599.
88. Dragojevic-Dikic S, Marisavljevic D, Mitrovic A, et al. An immunological insight into premature ovarian failure (POF). Autoimmun Rev, 2010, 9: 771-774.
89. Donnez J, Dolmans M M, Pirard C, et al. Allograft of ovarian cortex between two genetically non-identical sisters: case report. Hum Reprod, 2007, 22: 2653-2659.
90. Howard-Anderson J, Ganz P A, Bower J E, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst, 2012, 104: 386-405.
91. Fleischer R T, Vollenhoven B J, Weston G C. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv, 2011, 66: 248-254.
92. Clowse M E, Behera M A, Anders C K, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt), 2009, 18: 311-319.
93. Meirow D, Biederman H, Anderson R A, et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol, 2010, 53: 727-739.
94. Nicosia S V, Matus-Ridley M, Meadows A T. Gonadal effects of cancer therapy in girls. Cancer, 1985, 55: 2364-2372.
95. Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod, 2007, 22: 1626-1633.
96. Read M D, Edey K A, Hapeshi J, et al. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int, 2010, 16: 56-59.
97. Amato P, Roberts A C. Transient ovarian failure: a complication of uterine artery embolization. Fertil Steril, 2001, 75: 438-439.
98. Api M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol, 2009, 25: 159-165.
99. Prinz W, Taubert H D. Mumps in pubescent females and its effect on later reproductive function. Gynaecologia, 1969, 167: 23-27.
100. Morrison J C, Givens J R, Wiser W L, et al. Mumps oophoritis: a cause of premature menopause. Fertil Steril, 1975, 26: 655-659.
101. Cejtin H E, Kalinowski A, Bacchetti P, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol, 2006, 108: 1423-1431.
102. Ohl J, Partisani M, Demangeat C, et al. Alterations of ovarian reserve tests in Human Immunodeficiency Virus (HIV)-infected women. Gynecol Obstet Fertil, 2010, 38: 313-317.
103. Hoyer P B, Devine P J, Hu X, et al. Ovarian toxicity of 4-vinylcyclohexene diepoxide: a mechanistic model. Toxicol Pathol, 2001, 29: 91-99.
104. Christin-Maitre S, Ronci-Chaix N, Bouchard P. Ovary genes and molecular pathology. J Soc Biol, 2002, 196: 207-216.
105. De Miguel M P, Cheng L, Holland E C, et al. Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci USA, 2002, 99: 10458-10463.
106. Kappeler C J, Hoyer P B. 4-vinylcyclohexene diepoxide: a model chemical for ovotoxicity. Syst Biol Reprod Med, 2012, 58: 57-62.
107. Di Prospero F, Luzi S, Iacopini Z. Cigarette smoking damages women's reproductive life. Reprod Biomed Online, 2004, 8: 246-247.
108. Chang S H, Kim C S, Lee K S, et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas, 2007, 58: 19-30.
109. Kinney A, Kline J, Kelly A, et al. Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod, 2007, 22: 1175-1185.
110. Nardo L G, Christodoulou D, Gould D, et al. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol, 2007, 23: 486-493.
111. Matikainen T, Perez G I, Jurisicova A, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet, 2001, 28: 355-360.
112. Sharara F I, Seifer D B, Flaws J A. Environmental toxicants and female reproduction. Fertil Steril, 1998, 70: 613-622.
113. Klein P, Serje A, Pezzullo J C. Premature ovarian failure in women with epilepsy. Epilepsia, 2001, 42: 1584-1589.
114. Testa G, Chiaffarino F, Vegetti W, et al. Case-control study on risk factors for premature ovarian failure. Gynecol Obstet Invest, 2001, 51: 40-43.
115. Proetto Menopausa Italia Study Group, et al. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clinics in Italy. BJOG, 2003, 110: 59-63.
116. Henzl M R, Loomba P K. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med, 2003, 48: 525-540.
117. Jones S C. Subcutaneous estrogen replacement therapy. J Reprod Med, 2004, 49: 139-142.
118. Nelson H D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA, 2004, 291: 1610-1620.
119. Popat V B, Vanderhoof V H, Calis K A, et al. Normalization of serum luteinizing hormone levels in women with 46, XX spontaneous primary ovarian insufficiency. Fertil Steril, 2008, 89: 429-433.